Article
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
Breast cancer research : BCR - 28 May 2020
Clatot Florian, Perdrix Anne, Beaussire Ludivine, Lequesne Justine, Lévy Christelle, Emile George, Bubenheim Michael, Lacaille Sigrid, Calbrix Céline, Augusto Laetitia, Guillemet Cécile, Alexandru Cristina, Fontanilles Maxime, Sefrioui David, Burel Lucie, Guénot Sabine, Richard Doriane, Sarafan-Vasseur Nasrin, Di Fiore Frédéric
Abstract excerpt
BACKGROUND: Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting. We aimed to prospectively compare the risk of early progression according to circulating ESR1 mutations, CA-15.3, and circulating cell-free DNA in MBC patients treated with a first-line...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.